Parnax Lab

Parnax Lab Free Cash Flow

The Free Cash Flow (FCF) of Parnax Lab (506128.BO) as of Nov 14, 2026 is 137.24 M INR. In the previous year, Free Cash Flow (FCF) was -166.17 M INR — a change of -182.58% (higher).

Free Cash Flow

137.24 MINR

YoY

-182.58%

Last updated:

Free Cash Flow (FCF) of Parnax Lab is 2025 137.24 M INR. Free Cash Flow (FCF) of Parnax Lab was 2024 -166.17 M INR. It decreases by -182.58% higher compared to the previous year.

The Parnax Lab Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2018
76.53 M INR
Jan 1, 2019
-26.05 M INR
Jan 1, 2020
-44.36 M INR
Jan 1, 2021
-2.31 M INR
Jan 1, 2022
-92.82 M INR
Jan 1, 2023
96.30 M INR
Jan 1, 2024
-166.17 M INR
Jan 1, 2025
137.24 M INR
The Parnax Lab Free Cash Flow history
YEARFree Cash FlowYoY
137.24 MINR-182.58%
-166.17 MINR-272.56%
96.30 MINR-203.75%
-92.82 MINR+3,914.76%
-2.31 MINR-94.79%
-44.36 MINR+70.29%
-26.05 MINR-134.04%
76.53 MINR+982.94%
7.07 MINR-126.72%
-26.45 MINR-34.63%
-40.46 MINR-30.09%
-57.88 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Parnax Lab Stock analysis

What does Parnax Lab do? Parnax Lab Ltd. generates revenue through manufacturing and exporting pharmaceutical formulations, including cough expectorants, antacids, anti-histamines, multi-vitamins, enzyme preparations, pediatric formulations, geriatric special formulations, highly viscous products, and suspensions. The company trades pharmaceuticals and medicinal products, focusing on high-volume oral formulations for diverse consumer segments. Naxpar Pharma Private Limited serves as its subsidiary in these operations. The firm's primary customers are likely healthcare providers, pharmacies, and distributors within the pharmaceutical industry, though specific buyer details are not disclosed. Parnax Lab Ltd. operates through the pharmaceutical formulations segment, emphasizing export-driven manufacturing and trading activities. Its product portfolio targets various health needs, from pediatric to geriatric care, with a strong focus on oral delivery systems. Parnax Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Parnax Lab stock

Free Cash Flow (FCF) of Parnax Lab is 137.24 M INR in 2025.

Free Cash Flow (FCF) of Parnax Lab changed from -166.17 M INR to 137.24 M INR, representing a -182.58% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Parnax Lab since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Parnax Lab historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Parnax Lab

All Key Metrics — Parnax Lab